#BrazilSFE #Roche #Oncology #Haematology #Pharmaceuticals #Diagnostics #ResearchAndDevelopment #Innovation #Healthcare
A Roche reportou uma receita total de CHF 60,4 bilhões (USD 68,7 bilhões).
Pharmaceutical Income Statement List
- @Roche - FY24 - Income Statement
- @American Red Cross - FY23 - Income Statement
- @Johnson & Johnson - Q4 FY22 Income Statement
- @Johnson & Johnson - FY23 Income Statement
- @United Health - Q4 FY22 Income Statement
- @Procter & Gamble - Q2 FY23 Income Statement
- @Amgen - FY22 Income Statement
- @Merck - FY22 Income Statement
- @AbbVie Q1 FY24 Income Statement
- @Merck Q1 FY24 Income Statement
- @Eli Lilly Q2 FY24 Income Statement
- @Novartis FY24 Income Statement
VEJA TAMBÉM:🌐 2024 Pharm Exec Top 50
🌐 2023 Pharm Exec Top 50
🌐 2022 Pharm Exec Top 50
🌐 2022 Top 20 Empresas Brasileiras
🌐 2021 Pharm Exec Top 50
🌐 2020 Pharm Exec Top 50
🌐 2019 Pharm Exec Top 50
🌐 2018 Pharm Exec Top 50
🌐 2017 Pharm Exec Top 50
🌐 2016 Pharm Exec Top 50
🌐 2015 Pharm Exec Top 50
🌐 2014 Pharm Exec Top 50
🌐 2013 Pharm Exec Top 50
🌐 2012 Pharm Exec Top 50
🌐 2011 Pharm Exec Top 50
🌐 2010 Pharm Exec Top 50
A Roche apresentou um aumento de 7% em relação ao ano anterior (YoY), impulsionado pelos setores farmacêutico (CHF 46,2 bilhões / USD 52,5 bilhões) e diagnóstico (CHF 14,3 bilhões / USD 16,3 bilhões).
Pharmaceutical Income Statement List
@Roche - FY24 - Income Statement
@American Red Cross - FY23 - Income Statement
@Johnson & Johnson - Q4 FY22 Income Statement
@Johnson & Johnson - FY23 Income Statement
@United Health - Q4 FY22 Income Statement
@Procter & Gamble - Q2 FY23 Income Statement
@Amgen - FY22 Income Statement
@Merck - FY22 Income Statement
@AbbVie Q1 FY24 Income Statement
@Merck Q1 FY24 Income Statement
@Eli Lilly Q2 FY24 Income Statement
@Novartis FY24 Income Statement
Companies' Income Statement List
- Disney - Q1 FY25 - Income Statement
- Roblox - Q1 FY24 - Income Statement
- Arm Holdings - Q4 FY24 - Income Statement
- Uber - Q4 FY24 - Income Statement
- AMD - Q4 FY24 - Income Statement
- Alphabet - Q4 FY24 - Income Statement
- PayPal - Q4 FY24 - Income Statement
- Match Group - Q1 FY24 Income Statement
- Novo Nordisk Q1 FY24 Income Statement
- Alphabet Q1 FY24 Income Statement
- Amazon Q4 FY24 Income Statement
- Amazon Q4 FY23 Income Statement
- Meta Q2 FY24 Income Statement
- Meta Q1 FY24 Income Statement
- Alphabet Q4 FY24 Income Statement
- Microsoft Q2 FY25 Income Statement
- Apple Q1 FY25 Income Statement
- Oracle Q3 FY24 Income Statement
- Disney - Q1 FY25 - Income Statement
- Roblox - Q1 FY24 - Income Statement
- Arm Holdings - Q4 FY24 - Income Statement
- Uber - Q4 FY24 - Income Statement
- AMD - Q4 FY24 - Income Statement
- Alphabet - Q4 FY24 - Income Statement
- PayPal - Q4 FY24 - Income Statement
- Match Group - Q1 FY24 Income Statement
- Novo Nordisk Q1 FY24 Income Statement
- Alphabet Q1 FY24 Income Statement
- Amazon Q4 FY24 Income Statement
- Amazon Q4 FY23 Income Statement
- Meta Q2 FY24 Income Statement
- Meta Q1 FY24 Income Statement
- Alphabet Q4 FY24 Income Statement
- Microsoft Q2 FY25 Income Statement
- Apple Q1 FY25 Income Statement
- Oracle Q3 FY24 Income Statement
Os segmentos de oncologia (CHF 15,8 bilhões / USD 17,9 bilhões) e hematologia (CHF 7,9 bilhões / USD 8,9 bilhões) dominam seu portfólio farmacêutico.
A Roche investiu CHF 15,3 bilhões / USD 17,4 bilhões (24,5% da receita) em pesquisa e desenvolvimento (P&D).
👉 Não se esqueça de seguir André Bernardes no Linkedin ou assinar nossa newsletter 🔔 para ser notificado sobre todas as postagens. Clique aqui e me contate via What's App.
Nenhum comentário:
Postar um comentário
Compartilhe sua opinião e ponto de vista: